All In Biotech

Drug Trial Radar · NCT01621230

Effects of Bupivacaine Induced Motor Blockade During the Second Stage of Labor

A Randomized Double-blinded Trial of the Effects of Bupivacaine Induced Motor Blockade on the Second Stage of Labor

Last checked: Nov 20, 2026Latest source record: Aug 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 481 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

481

Actual

Start

Sep 2009

Primary completion

Jul 2012

Study completion Jul 2013

Sponsor

Lead sponsor
University of Texas Southwestern Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 18, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Female only, from 16 years, up to 44 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of this study is to measure the effects of bupivacaine administered via epidural catheters on indices of motor blockade ascertained during the second stage of labor. This is a randomized, double-blind, controlled trial designed to address the primary research question: Does bupivacaine lengthen the second stage of labor? The secondary research question is: Is there other evidence of motor blockade attributable to bupivacaine during the second stage of labor? The investigators know from prior studies that the length of the second stage in nulliparous women delivered at Parkland Hospital without epidural analgesia is 28 minutes. The investigators hypothesize in this now proposed study that epidural analgesia with bupivacaine will significantly increase this baseline from 28 minutes to 37 minutes or more (a 33% increase) thus implicating motor blockade. Baseline data for the Bromage and Breen scores during the second stage as well as the uterine contractility data are not available as these indices of motor blockade have not here-to-fore been studied in this context. Currently at Parkland Hospital, 82% of nulliparous women undergoing induction of labor at term receive continuous epidural infusions with bupivacaine during the first and second stages of labor. Such women will be identified when admitted for scheduled inductions at Parkland. After informed consent is obtained standard management of labor induction will be provided. Those consented women reaching 8 cm cervical dilation will be randomized. Group I will receive bupivacaine plus fentanyl via epidural catheter during the second stage (i.e. 10 cm dilation) and Group II will receive only fentanyl infusion via epidural catheter (see study procedure below). Both the patient and the caregiver will be blinded as to whether the patient is in the bupivacaine plus fentanyl arm or the fentanyl only arm. To detect a 33% increase (from 28 minutes to 37 minutes) in the primary outcome the investigators need a total of 310 women enrolled in the study (or 155 per arm). Assuming a 30% consent rate and given that approximately 1000 women meet the inclusion criteria each year at Parkland, the investigators project that this study could be completed in 12 months.

Conditions

  • Pregnancy

Interventions

  • Epidural Bupivacaine plus fentanylDrug

    The subjects will receive 0.125% bupivacaine with fentanyl 2 mcg/mL at a rate of 10 mL/hr.

  • Epidural fentanylDrug

    The subjects will receive epidural fentanyl 10 mcg/mL with the rate of 10mL/hr.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Duration of the Second Stage of LaborTime frame: Duration of second stage of labor approximately 30 minutes to 150 minutes

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Parkland Health and Hospital System

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.